ЛІКУВАННЯ ХВОРИХ З COVID-19 НА СУЧАСНОМУ ЕТАПІ
DOI:
https://doi.org/10.11603/1681-2727.2020.3.11548Ключові слова:
COVID-19, лікуванняАнотація
На підставі огляду наукової літератури висвітлено сучасні підходи до лікування хворих на COVID-19. Наведено показання до госпіталізації хворих і дані про ефективність препаратів з різним механізмом дії, враховуючи міжнародний досвід. Відзначено, що широка апробація ремдезивіру, гідроксихлорохіну, лопінавіру-ритонавіру, інтерферонів не дала переконливих результатів. Надія з’явилася щодо використання плазми реконвалесцентів і моноклональних антитіл до вірусу, які, однак, потребують ретельної багатоцентрової апробації. Водночас, певних успіхів досягнуто в патогенетичній терапії. Чітко обґрунтовано показання, строки призначення і оптимальні дози кортикостероїдів, інгібіторів інтерлейкінів (тоцилізумаб), антикоагулянтів, переважно низькомолекулярних похідних гепарину, під контролем рівня D-димеру та інших показників гемостазу. Антибіотики рекомендовано призначати при приєднанні бактерійної ко-інфекції, що спостерігається нечасто. Стаття адресована головно для лікарів, які працюють з хворими на COVID-19.
Посилання
Kupferschmidt, K., & Cohen, J. (2020). Race to find COVID-19 treatments accelerates. Science, 367(6485), 1412-1413. DOI: https://doi.org/10.1126/science.367.6485.1412
Xie, J., Tong, Z., Guan, X., Du, B., Qiu, H., & Slutsky, A. S. (2020). Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive care medicine, 1-4. DOI: https://doi.org/10.1007/s00134-020-05979-7
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., ... & Bannister, R. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine, 9(396). DOI: https://doi.org/10.1126/scitranslmed.aal3653
Grein, J., Ohmagari, N., & Shin, D. (2020).Original: Compassionate Use of Remdesivir for Patients with Severe Covid-19. doi: 10.1056/NEJMoa2007016. DOI: https://doi.org/10.1056/NEJMoa2007016
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., ... & Hu, Y. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569-78.
FDA Approves First Treatment for COVID-19. (2020). https://www.fda.gov. Retrieved from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19?fbclid=IwAR2ApWo5KoG1tSDAEY4B1LPYAXwcbggqI8rfuFYyw368XxTwBox2g7Tthng. DOI: https://doi.org/10.1002/cpu.30542
Preliminary Report of the Favipiravir Observational Study in Japan. (2020). http://www.kansensho.or.jp. Retrieved from: http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf.
Doi, K., Ikeda, M., Hayase, N., Moriya, K., & Morimura, N. (2020). Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Critical Care, 24(1), 1-4. DOI: https://doi.org/10.1186/s13054-020-03078-z
Fact sheet for health care providers emergency use authorization (eua) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of covid-19 in certain hospitalized patients. (2020). https://www.fda.gov. Retrieved from: https://www.fda.gov/media/136537/download.
Sbidian, E., Josse, J., Lemaitre, G., Mayer, I., Bernaux, M., Gramfort, A., ... & Garcelon, N. (2020). Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France. MedRxiv. DOI: 10.1101/2020.06.16.20132597. DOI: https://doi.org/10.1101/2020.06.16.20132597
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., ... & Li, X. (2020). A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine, 382, 1787-1799. DOI: https://doi.org/10.1056/NEJMc2008043
Pan, H., Peto, R., Karim, Q. A., Alejandria, M., Restrepo, A. M. H., Garcia, C. H., ... & Reddy, S. (2020). Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. medRxiv. https://www.medrxiv.org. Retrieved from: https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1?ijkey=20cacba9e914a4fca24a25660e28ee34175f6959&keytype2=tf_ipsecsha.
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., ... & Wei, J. (2020). Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama, 323(16), 1582-1589. DOI: https://doi.org/10.1001/jama.2020.4783
Zeng, Q. L., Yu, Z. J., Gou, J. J., Li, G. M., Ma, S. H., Zhang, G. F., ... & Li, C. (2020). Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. The Journal of infectious diseases, 222(1), 38-43. DOI: https://doi.org/10.1093/infdis/jiaa228
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., ... & Peng, C. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences, 117(17), 9490-9496. DOI: https://doi.org/10.1073/pnas.2004168117
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., ... & Roh, J. (2020). Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean medical science, 35(14), e149. DOI: https://doi.org/10.3346/jkms.2020.35.e149
Figlerowicz, M., Mania, A., Lubarski, K., Lewandowska, Z., Służewski, W., Derwich, K., ... & Mazur-Melewska, K. (2020). First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia. Transfusion and Apheresis Science, 102866. DOI: https://doi.org/10.1016/j.transci.2020.102866
Xu, Y., Xu, Z., Liu, X., Cai, L., Zheng, H., Huang, Y., ... & Li, J. (2020). Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong Province, China: a multi-center, retrospective, observational study. medRxiv. https://www.medrxiv.org. Retrieved from: http:// medrxiv.org/lookup/doi/10.1101/2020.05.20.20102236. DOI: https://doi.org/10.1101/2020.03.03.20030668
Casadevall, A., & Scharff, M. D. (1995). Return to the past: the case for antibody-based therapies in infectious diseases. Clinical infectious diseases, 21(1), 150-161. DOI: https://doi.org/10.1093/clinids/21.1.150
Casadevall, A., Joyner, M. J., & Pirofski, L. A. (2020). A Randomized Trial of Convalescent Plasma for COVID-19 – Potentially Hopeful Signals. JAMA. https://jamanetwork.com. Retrieved from: https:// jamanetwork.com/journals/jama/fullarticle/2766940. DOI: https://doi.org/10.1001/jama.2020.10218
V Ukraini zavershyly klinichni vyprobuvannia preparatu «Bioven» dlia likuvannia COVID-19 (Clinical trials of Bioven for the treatment of COVID-19 have been completed in Ukraine). (2020). Ukrinform. https://www.ukrinform.ua. Retrieved from: https://www.ukrinform.ua/rubric-society/3136202-v-ukraini-zaversili-klinicni-viprobuvanna-preparatu-bioven-dla-likuvanna-covid19.html.
Кomisaronko, S. (2020). Svitova koronavirusna kryza (World coronavirus crisis). LАТ&K, 120 p. [in Ukrainian].
Christopher, B. (2020). An ACE therapy for COVID-19. Science Translational Medicine. 541(12), DOI: 10.1126/scitranslmed.abb5676. DOI: https://doi.org/10.1126/scitranslmed.abb5676
Kramer. J. (2020). Coronavirus Antibody Therapies Raise Hopes and Skepticism. Scientificamerican. https://www.scientificamerican.com. Retrieved from: https://www.scientificamerican.com/article/coronavirus-antibody-therapies-raise-hopes-and-skepticism1/.
Owence, C. (2020). The good and bad news about coronavirus antibody therapies. Axios. https://www.axios.com. Retrieved from: https://www.axios.com/coronavirus-antibody-treatment-regeneron-cost-availability-e324c8b9-b857-42a8-8472-3b6040163a63.html.
FDA. (2020). Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. FDA News Release. https://www.fda.gov. Retrieved from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19.
World Health Organization. (2020). Corticosteroids for COVID-19: living guidance, 2 September 2020 (No. WHO/2019-nCoV/Corticosteroids/2020.1). https://www.who.int. Retrieved from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1.
Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Izcovich, A., Kum, E., ... & Liu, Q. (2020). Drug treatments for covid-19: living systematic review and network meta-analysis. bmj, 370. https://www.bmj.com. Retrieved from: https://www.bmj.com/content/370/bmj.m2980).
Sterne, J. A., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., ... & Dequin, P. F. (2020). Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama. https://jamanetwork.com. Retrieved from: https://jamanetwork.com/journals/jama/article-abstract/2770279)
Lamontagne, F., Agoritsas, T., Macdonald, H., Leo, Y. S., Diaz, J., Agarwal, A., ... & Cao, B. (2020). A living WHO guideline on drugs for covid-19. Bmj, 370. https://www.bmj.com. Retrieved from: https://www.bmj.com/content/370/bmj.m3379.
European Medicines Agency. EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation. (2020). https://www.ema.europa.eu. Retrieved from: https://www.ema.europa.eu/en/news/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-mechanical-ventilation.
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, V. C. C., ... & Shoham, S. (2020). Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clinical Infectious Diseases. https://www.idsociety.org. Retrieved from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. DOI: https://doi.org/10.1093/cid/ciaa478
Aziz, M., Haghbin, H., Sitta, E. A., Nawras, Y., Fatima, R., Sharma, S., ... & Assaly, R. (2020). Efficacy of Tocilizumab in COVID-19: A Systematic review and Meta-Analysis. Journal of Medical Virology. https://onlinelibrary.wiley.com. Retrieved from: https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26509. DOI: https://doi.org/10.1002/jmv.26509
Furlow, B. (2020). COVACTA trial raises questions about tocilizumab’s benefit in COVID-19. The Lancet Rheumatology, 2(10), e592. DOI: https://doi.org/10.1016/S2665-9913(20)30313-1
National Institutes of Health. (2020). Coronavirus disease 2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov. Retrieved from: https://www.covid19treatmentguidelines.nih.gov/whats-new/
Cavalli, G., De Luca, G., Campochiaro, C., Della-Torre, E., Ripa, M., Canetti, D., ... & Tomelleri, A. (2020). Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology. https://www.ncbi.nlm.nih.gov/Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252085/. DOI: https://doi.org/10.1016/S2665-9913(20)30127-2
Navarro-Millán, I., Sattui, S. E., Lakhanpal, A., Zisa, D., Siegel, C. H., & Crow, M. K. (2020). Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series. Arthritis & Rheumatology. https://onlinelibrary.wiley.com. Retrieved from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41422. DOI: https://doi.org/10.1002/art.41422
National Institute for Health and Care Excellence. (2020). COVID 19 rapid evidence summary: anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis. 2020. https://www.nice.org.uk. Retrieved from: https://www.nice.org.uk/advice/es26/chapter/Key-messages.
Barnes, G. D., Burnett, A., Allen, A., Blumenstein, M., Clark, N. P., Cuker, A., ... & Kaatz, S. (2020). Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis, 1. https://link.springer.com. Retrieved from: https://link.springer.com/article/10.1007/s11239-020-02138-z. DOI: https://doi.org/10.1007/s11239-020-02138-z
Moores, L. K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J. F., Doerschug, K., ... & Wells, P. (2020). Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest, 158(3), 1143-1163. DOI: https://doi.org/10.1016/j.chest.2020.05.559
American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. (2020). https://www.hematology.org. Retrieved from: https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation.
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., ... & Tang, L. V. (2020). COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 75(23), 2950-2973. DOI: https://doi.org/10.1016/j.jacc.2020.04.031
World Health Organization. (2020). Clinical management of COVID-19: interim guidance, 27 May 2020 (No. WHO/2019-nCoV/clinical/2020.5). https://www.who.int. Retrieved from: https://www.who.int/publications/i/item/clinical-management-of-covid-19.
Nadkarni, G. N., Lala, A., Bagiella, E., Chang, H. L., Moreno, P., Pujadas, E., ... & Cordon-Cardo, C. (2020). Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study. Journal of the American College of Cardiology. https://www.ncbi.nlm.nih.gov. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449655/. DOI: https://doi.org/10.1016/j.jacc.2020.08.041
Boretti, A., & Banik, B. K. (2020). Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition, 100190. https://www.ncbi.nlm.nih.gov. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172861/. DOI: https://doi.org/10.1016/j.phanu.2020.100190
Vitamin, C. (2020). infusion for the treatment of severe 2019-nCOV infected pneumonia. https://clinicaltrials.gov. Retrieved from: https://clinicaltrials.gov/ct2/show/NCT04264533. Accessed April, 16.
Grant, W. B., Lahore, H., McDonnell, S. L., Baggerly, C. A., French, C. B., Aliano, J. L., & Bhattoa, H. P. (2020). Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients, 12(4), 988. DOI: https://doi.org/10.3390/nu12040988
Vitamin D on prevention and treatment of COVID-19 (COVITD-19). (2020). https://clinicaltrials.gov . Retrieved from: https://clinicaltrials.gov/ct2/show/NCT04334005.
Castillo, M. E., Costa, L. M. E., Barrios, J. M. V., Díaz, J. F. A., Miranda, J. L., Bouillon, R., & Gomez, J. M. Q. (2020). Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. The Journal of steroid biochemistry and molecular biology, 203, 105751. DOI: https://doi.org/10.1016/j.jsbmb.2020.105751
National Institute for Health and Care Excellence. (2020). COVID-19 rapid evidence summary: vitamin D for COVID-19. https://www.nice.org.uk. Retrieved from: https://www.nice.org.uk/advice/es28/chapter/Key-messages.
Dhar, D., & Mohanty, A. (2020). Gut microbiota and Covid-19-possible link and implications. Virus Research, 198018. https://www.sciencedirect.com. Retrieved from: https://www.sciencedirect.com/science/article/pii/S0168170220304603?via%3Dihub. DOI: https://doi.org/10.1016/j.virusres.2020.198018
Mak, J. W., Chan, F. K., & Ng, S. C. (2020). Probiotics and COVID-19–Authors’ reply. The Lancet Gastroenterology & Hepatology, 5(8), 722-723. DOI: https://doi.org/10.1016/S2468-1253(20)30197-7
Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease. (2020). https://www.cdc.gov. Retrieved from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.
Andreychyn, M. A., Nychyk, N. A., Zavidniuk, N. H., Iosyk, I. I., Ischuk, I. S., & Ivakhiv, O. L. (2020). COVID-19: epidemiolohiia, klinika, diahnostyka, likuvannia ta profilaktyka (COVID-19: epidemiology, clinic, diagnostics, treatment and prevention). Infektsiini khvoroby, (2), 41-55. [in Ukrainian].
National Institute for Health and Care Excellence. (2020). COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. https://www.nice.org.uk. Retrieved from: https://www.nice.org.uk/guidance/ng173.
Metlay, J. P., & Waterer, G. W. (2020). Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic. https://www.acpjournals.org. Retrieved from: https://www.acpjournals.org/doi/10.7326/M20-2189. DOI: https://doi.org/10.7326/M20-2189
Antimicrobial Stewardship in COVID-19. (2020). https://www.hpsc.ie. Retrieved from: ttps://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/guidance/infectionpreventionandcontrolguidance/antimicrobialstewardship/Antimicrobial%20Stewardship%20in%20COVID%2019.pdf.
COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. (2020). https://www.nice.org.uk. Retrieved from: https://www.nice.org.uk/guidance/ng165/resources/covid19-rapid-guideline-managing-suspected-or-confirmed-pneumonia-in-adults-in-the-community-pdf-66141902429125.
Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. (2020). https://www.mp.pl. Retrieved from: https://www.mp.pl/paim/en/node/15270/pdf.
Clinical management of patients with COVID-19: Second interim guidance. (2020). https://www.canada.ca. Retrieved from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/clinical-management-covid-19.html.
Protocolul de tratament al infecției cu virusul SARS-Cov-2, din 26.03.2020. https://www.cnscbt.ro. Retrieved from: https://www.cnscbt.ro/index.php/legislatie_cov/1617-protocolul-de-tratament-covid-19/file.
Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. (2020). https://www.who.int. Retrieved from: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf.
Nakaz MOZ Ukrainy vid 11.11.2020 № 2583 “Pro vnesennia zmin do Standartiv medychnoi dopomohy “Koronavirusna khvoroba (COVID-19)” [Order of the Ministry of Health of Ukraine dated 11.11.2020 No. 2583 “On Amendments to the Standards of Medical Care “Coronavirus Disease (COVID-19)”]. zakon.rada.gov.ua. Retrieved from: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-11112020--2583-pro-vnesennja-zmin-do-protokolu--nadannja-medichnoi-dopomogi-dlja-likuvannja--koronavirusnoi-hvorobi-covid-19 [in Ukrainian].
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Автори, які публікуються у цьому журналі, погоджуються з наступними умовами:
- Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи, яка через [ВКАЖІТЬ ПЕРІОД ЧАСУ] з дати публікації автоматично стає доступною на умовах ліцензії Creative Commons Attribution License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.
- Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
- Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
